StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

UroGen Pharma's profit margin for the twelve months ending Jun 30, 2026 was -51.7%. For fiscal 2025 it was -139.8%, against -140.4% the year before. The highest annual figure on record is -11.1% in fiscal 2016.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-139.8%+0.5
FY2024Dec 31, 2024-140.4%−16.7
FY2023Dec 31, 2023-123.6%+47.0
FY2022Dec 31, 2022-170.6%+60.1
FY2021Dec 31, 2021-230.7%+858.3
FY2020Dec 31, 2020-1088.9%+583055.5
FY2019Dec 31, 2019-584144.4%−577437.3
FY2018Dec 31, 2018-6707.2%−6462.0
FY2017Dec 31, 2017-245.2%−234.1
FY2016Dec 31, 2016-11.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-19.8%+186.4
Q1 FY2026Mar 31, 2026-46.3%+170.2
Q4 FY2025Dec 31, 2025-69.7%+83.0
Q3 FY2025Sep 30, 2025-121.3%−27.4
Q2 FY2025Jun 30, 2025-206.2%−53.3
Q1 FY2025Mar 31, 2025-216.5%−44.6
Q4 FY2024Dec 31, 2024-152.7%−42.1
Q3 FY2024Sep 30, 2024-93.9%+11.0
Q2 FY2024Jun 30, 2024-152.9%−38.7
Q1 FY2024Mar 31, 2024-171.9%+3.8
Q4 FY2023Dec 31, 2023-110.6%+49.0
Q3 FY2023Sep 30, 2023-104.9%+55.5
Q2 FY2023Jun 30, 2023-114.2%+46.6
Q1 FY2023Mar 31, 2023-175.7%+33.6
Q4 FY2022Dec 31, 2022-159.6%+16.3
Q3 FY2022Sep 30, 2022-160.5%+105.7
Q2 FY2022Jun 30, 2022-160.8%+40.5
Q1 FY2022Mar 31, 2022-209.3%+137.2
Q4 FY2021Dec 31, 2021-175.9%+207.3
Q3 FY2021Sep 30, 2021-266.2%+566.4
Q2 FY2021Jun 30, 2021-201.2%+8225.9
Q1 FY2021Mar 31, 2021-346.5%+124525.7
Q4 FY2020Dec 31, 2020-383.2%+6872.3
Q3 FY2020Sep 30, 2020-832.6%+4119.6
Q2 FY2020Jun 30, 2020-8427.2%−5645.0
Q2 FY2019Jun 30, 2019-124872.2%−121787.8
Q3 FY2018Sep 30, 2018-7255.5%−7251.7
Q2 FY2018Jun 30, 2018-4952.2%+13032.0
Q1 FY2018Mar 31, 2018-2782.1%–
Q4 FY2017Dec 31, 2017-3084.4%–
Q3 FY2017Sep 30, 2017-3.8%–
Q1 FY2017Mar 31, 2017-17984.2%–

More UroGen Pharma figures

See a number that looks wrong?